| abstract |
The invention provides specific compounds and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers. The present invention describes methods of treating a subject having a particular disease state that is responsive to inhibition of transglutaminase TG2 activity. These disease states include neurodegenerative disorders such as Huntington's disease. The invention also describes a method of treatment comprising administering at least one compound or a pharmaceutically acceptable salt thereof as a single active agent, or at least one compound or a pharmaceutically acceptable salt thereof, and one or more other therapeutic agents Combination administration. |